New Immune-Boosting combo targets Tough-to-Treat sarcomas
NCT ID NCT03282344
Summary
This study is testing whether combining two immunotherapy drugs, NKTR-214 and nivolumab, can help control advanced sarcoma. It is for patients aged 12 and older whose cancer has progressed after at least one prior treatment. The main goal is to see how many patients' tumors shrink or stop growing with this combination therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center (only recruiting to the Vascular/Angiosarcoma cohort)
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center (only recruiting to the Vascular/Angiosarcoma cohort)
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.